163 related articles for article (PubMed ID: 32063702)
1. Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
Kurian N; Cohen TS; Öberg L; De Zan E; Skogberg G; Vollmer S; Baturcam E; Svanberg P; Bonn B; Smith PD; Vaarala O; Cunoosamy DM
Int J Chron Obstruct Pulmon Dis; 2019; 14():2611-2624. PubMed ID: 32063702
[TBL] [Abstract][Full Text] [Related]
2. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
4. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells.
Higham A; Karur P; Jackson N; Cunoosamy DM; Jansson P; Singh D
Int J Chron Obstruct Pulmon Dis; 2018; 13():1279-1288. PubMed ID: 29719383
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
Nan XY; Wu Y; Zhang LH; Yang ZJ
Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
[TBL] [Abstract][Full Text] [Related]
6. Small molecule-based inhibition of MEK1/2 proteins dampens inflammatory responses to malaria, reduces parasite load, and mitigates pathogenic outcomes.
Wu X; Dayanand KK; Thylur RP; Norbury CC; Gowda DC
J Biol Chem; 2017 Aug; 292(33):13615-13634. PubMed ID: 28679535
[TBL] [Abstract][Full Text] [Related]
7. MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant
De M; Serpa G; Zuiker E; Hisert KB; Liles WC; Manicone AM; Hemann EA; Long ME
Front Cell Infect Microbiol; 2024; 14():1275940. PubMed ID: 38352056
[TBL] [Abstract][Full Text] [Related]
8. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs.
Gaffey K; Reynolds S; Plumb J; Kaur M; Singh D
Eur Respir J; 2013 Jul; 42(1):28-41. PubMed ID: 23060629
[TBL] [Abstract][Full Text] [Related]
9. p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis.
Grethe S; Pörn-Ares MI
Cell Signal; 2006 Apr; 18(4):531-40. PubMed ID: 15972258
[TBL] [Abstract][Full Text] [Related]
10. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Sharma-Walia N; Krishnan HH; Naranatt PP; Zeng L; Smith MS; Chandran B
J Virol; 2005 Aug; 79(16):10308-29. PubMed ID: 16051824
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
12. Off-target effects of MEK inhibitors.
Wauson EM; Guerra ML; Barylko B; Albanesi JP; Cobb MH
Biochemistry; 2013 Aug; 52(31):5164-6. PubMed ID: 23848362
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
14. MEK1/2 Inhibition Promotes Macrophage Reparative Properties.
Long ME; Eddy WE; Gong KQ; Lovelace-Macon LL; McMahan RS; Charron J; Liles WC; Manicone AM
J Immunol; 2017 Jan; 198(2):862-872. PubMed ID: 28003382
[TBL] [Abstract][Full Text] [Related]
15. MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.
Yang L; Ding JL
Front Immunol; 2019; 10():2020. PubMed ID: 31507609
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.
Xiao L; Pimental DR; Amin JK; Singh K; Sawyer DB; Colucci WS
J Mol Cell Cardiol; 2001 Apr; 33(4):779-87. PubMed ID: 11273730
[TBL] [Abstract][Full Text] [Related]
18. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
